secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040564
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q2 2023 net loss narrows to $3.3M; cash $48.4M; stock repurchase authorized
--------------------------------------------------------------------------------

- Revenue of $9.1M from Ono partnership; net loss $0.10/sh vs $0.41/sh loss year ago.
- Cash and investments $48.4M at June 30; fully prepaid and retired debt facility.
- Authorized $7.5M stock repurchase program; cash runway expected into 2025.
- Promoted Dr. Maple Fung to Chief Medical Officer; EQ101 alopecia areata data due 2H 2023.
- Ono option for itolizumab could bring ~$35M; EQUALISE lupus nephritis topline early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000095017023040564/0000950170-23-040564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000095017023040564/eq-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer